{
  "paper_id": "50182118c28e586765a227b90fd9c4f3c584d366",
  "metadata": {
    "title": "The efficacy of intranasal interferonet-2a in respiratory syncytial virus infection in volunteers",
    "coda_data_split": "test",
    "coda_paper_id": 57,
    "coda_has_expert_labels": false,
    "subset": "custom_license"
  },
  "abstract": [
    {
      "original_text": "In a double-blind, placebo-controlled study, self-administered intranasal interferona-2a or placebo was given both before and after challenge with respiratory syncytial virus. The incidence of colds and the severity of signs and symptoms were reduced in those receiving interferonot-2a as compared with those given placebo.",
      "sentences": [
        [
          {
            "segment_text": "In a double-blind , placebo-controlled study ,",
            "crowd_label": "background"
          },
          {
            "segment_text": "self-administered intranasal interferona-2a or placebo was given both before and after challenge with respiratory syncytial virus .",
            "crowd_label": "method"
          }
        ],
        [
          {
            "segment_text": "The incidence of colds and the severity of signs and symptoms were reduced in those receiving interferonot-2a as compared with those given placebo .",
            "crowd_label": "method"
          }
        ]
      ]
    },
    {
      "original_text": "In a further double-blind, placebo-controlled study, self-administered interferonot-2a or placebo was given only to those volunteers who developed colds following challenge with respiratory syncytial virus. There was no evidence that interferon~t-2a reduced the severity of the signs and symptoms or shortened the duration of the illness.",
      "sentences": [
        [
          {
            "segment_text": "In a further double-blind , placebo-controlled study ,",
            "crowd_label": "method"
          },
          {
            "segment_text": "self-administered interferonot-2a or placebo was given only to those volunteers who developed colds following challenge with respiratory syncytial virus .",
            "crowd_label": "method"
          }
        ],
        [
          {
            "segment_text": "There was no evidence that interferon ~ t-2a reduced the severity of the signs and symptoms or shortened the duration of the illness .",
            "crowd_label": "finding"
          }
        ]
      ]
    },
    {
      "original_text": "The similarity of these results to the effect of interferonot-2a in rhinovirus infections in volunteers is discussed.",
      "sentences": [
        [
          {
            "segment_text": "The similarity of these results to the effect of interferonot-2a in rhinovirus infections in volunteers is discussed .",
            "crowd_label": "finding"
          }
        ]
      ]
    }
  ],
  "abstract_stats": {
    "paragraph_num": "3",
    "sentence_num": "5",
    "segment_num": "7",
    "token_num": "118"
  }
}